Plasma-Based Proteomic Platform Predicts
Clinical Benefit from Immune-Checkpoint Inhibitors in NSCLC,
Melanoma, and HPV-Related Cancers
BINYAMINA, Israel and CARY, N.C., May 23, 2024
/PRNewswire/ -- OncoHost, a technology
company transforming the approach to precision medicine for
improved patient outcomes, today announced that it has been
accepted for a poster presentation at the upcoming American Society
of Clinical Oncology (ASCO) Annual Meeting, to be held
from May 31 to June 4, 2024, in
Chicago, Illinois. The
presentation will highlight the ability of the company's
PROphet® platform to predict clinical benefit from immune
checkpoint inhibitor (ICI)-based therapies across
various cancer indications.
"ICIs represent a key treatment modality for a growing number of
cancer types, but a gap exists in the availability of predictive
tests that can accurately identify patients likely to benefit from
these therapies. Our PROphet® platform offers a solution," said
Ofer Sharon, MD, CEO at OncoHost.
"This research highlights the adaptability of PROphet® as we work
to provide treatment guidance for multiple indications. I am proud
of our team's commitment to improving outcomes for cancer patients
worldwide and the ongoing impact of our work in the oncology
field."
PROphet® is a novel and robust predictive computational model
that analyzes and identifies proteomic profiles in pre-treatment
blood plasma by combining bioinformatics, system biology, proteomic
pattern recognition and machine learning. PROphetNSCLC™, the first
indication for which the platform was developed, predicts clinical
benefit from first-line PD-1/PD-L1 inhibitor-based therapies in
patients with metastatic non-small cell lung cancer (mNSCLC),
offering guidance in choosing between ICI monotherapy and
ICI-chemotherapy combination.
For this observational study, pre-treatment plasma samples and
clinical data were collected from patients with metastatic melanoma
and HPV-related cancers undergoing treatment with PD-1/PD-L1
inhibitor-based therapies. HPV-related cancers included anogenital
squamous cell carcinoma, cervical carcinoma, and head and neck
squamous cell carcinoma. The presentation will showcase the
findings which demonstrate the potential of the PROphetNSCLC™ test
in predicting ICI response for indications beyond just NSCLC,
underscoring the promise of PROphet® in advancing precision
medicine.
The study was conducted in collaboration with Sidney Kimmel
Medical College at Thomas Jefferson
University, Yale School of
Medicine, and the Center for Immuno-Oncology, Center
for Cancer Research of the National Cancer Institute.
"We are excited to present our latest findings at ASCO 2024,"
said Itamar Sela, Ph.D., VP R&D
at OncoHost and co-author of the study. "This study showcases the
versatility of the PROphet® platform in predicting benefit from
immune-checkpoint inhibitors not only in NSCLC, but also in
melanoma and HPV-related cancers. By leveraging the power of
plasma-based proteomic analysis, PROphet® offers a non-invasive and
efficient method to guide treatment decisions and optimize patient
care."
Poster Presentation Details
Session:
Developmental Therapeutics—Immunotherapy
Abstract
#: 2568
Poster Bd
#: 47
Title: A plasma-based
proteomic platform for predicting clinical benefit from immune
checkpoint inhibitors in multiple cancers.
Presenter: Itamar
Sela, Ph.D., VP R&D at
OncoHost
Date/Time: 6/1/2024,
9:00 AM-12:00 PM CDT
The abstract is available on the ASCO website.
About OncoHost
OncoHost is a technology company
headquartered in Binyamina, Israel, and Cary,
North Carolina, transforming the approach to precision
medicine for improved patient outcomes. OncoHost's proprietary
platform, PROphet®, is a plasma-based, proteomic pattern analysis
tool whose initial offering in non-small cell lung cancer (NSCLC)
uses a single blood sample to guide first-line immunotherapy
decision-making. The PROphetNSCLC™ test provides clear
clinical utility by offering physicians crucial guidance on the
optimal first-line immunotherapy treatment plan for each individual
patient, with a significant effect on overall survival. Led by an
experienced team of entrepreneurs and industry experts and
supported by a large-scale prospective clinical trial with over 40
sites and 1,700 patients recruited worldwide, OncoHost is
well-positioned to lead precision diagnostics and biomarker
development to the next stage.
For more information, visit www.oncohost.com, or follow OncoHost
on LinkedIn, Twitter, Facebook and YouTube.
Media Contact:
Lior
Alperovich
Marcom Manager
lior@oncohost.com
+972-54-282-4503
View original
content:https://www.prnewswire.com/news-releases/oncohost-to-present-poster-demonstrating-prophets-application-in-multiple-cancer-indications-at-asco-2024-302154326.html
SOURCE OncoHost